160 related articles for article (PubMed ID: 8546206)
1. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line.
Hashimoto K; Tsujimura T; Moriyama Y; Yamatodani A; Kimura M; Tohya K; Morimoto M; Kitayama H; Kanakura Y; Kitamura Y
Am J Pathol; 1996 Jan; 148(1):189-200. PubMed ID: 8546206
[TBL] [Abstract][Full Text] [Related]
2. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.
Kitayama H; Kanakura Y; Furitsu T; Tsujimura T; Oritani K; Ikeda H; Sugahara H; Mitsui H; Kanayama Y; Kitamura Y
Blood; 1995 Feb; 85(3):790-8. PubMed ID: 7530509
[TBL] [Abstract][Full Text] [Related]
3. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
5. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
6. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
Piao X; Bernstein A
Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325
[TBL] [Abstract][Full Text] [Related]
7. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
[TBL] [Abstract][Full Text] [Related]
8. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of Trp53 rescues the male fertility defects of Kit(W-v) mice but has no effect on the survival of melanocytes and mast cells.
Jordan SA; Speed RM; Bernex F; Jackson IJ
Dev Biol; 1999 Nov; 215(1):78-90. PubMed ID: 10525351
[TBL] [Abstract][Full Text] [Related]
10. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Ning ZQ; Li J; McGuinness M; Arceci RJ
Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
[TBL] [Abstract][Full Text] [Related]
11. Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement.
Caruana G; Cambareri AC; Gonda TJ; Ashman LK
Oncogene; 1998 Jan; 16(2):179-90. PubMed ID: 9464535
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and differentiation of spermatogonial stem cells in the w/wv mutant mouse testis.
Ohta H; Tohda A; Nishimune Y
Biol Reprod; 2003 Dec; 69(6):1815-21. PubMed ID: 12890724
[TBL] [Abstract][Full Text] [Related]
13. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.
Isozaki K; Terris B; Belghiti J; Schiffmann S; Hirota S; Vanderwinden JM
Am J Pathol; 2000 Nov; 157(5):1581-5. PubMed ID: 11073817
[TBL] [Abstract][Full Text] [Related]
14. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases.
Eklund KK; Ghildyal N; Austen KF; Stevens RL
J Immunol; 1993 Oct; 151(8):4266-73. PubMed ID: 7691943
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Kit expression by IL-4 and IL-10 in murine mast cells: role of STAT6 and phosphatidylinositol 3'-kinase.
Mirmonsef P; Shelburne CP; Fitzhugh Yeatman C; Chong HJ; Ryan JJ
J Immunol; 1999 Sep; 163(5):2530-9. PubMed ID: 10452990
[TBL] [Abstract][Full Text] [Related]
16. The role of Ets-1 in mast cell granulocyte-macrophage colony-stimulating factor expression and activation.
McKinlay LH; Tymms MJ; Thomas RS; Seth A; Hasthorpe S; Hertzog PJ; Kola I
J Immunol; 1998 Oct; 161(8):4098-105. PubMed ID: 9780181
[TBL] [Abstract][Full Text] [Related]
17. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
Samayawardhena LA; Hu J; Stein PL; Craig AW
Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
[TBL] [Abstract][Full Text] [Related]
18. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.
Lam LP; Chow RY; Berger SA
Biochem J; 1999 Feb; 338 ( Pt 1)(Pt 1):131-8. PubMed ID: 9931308
[TBL] [Abstract][Full Text] [Related]
19. Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo.
Mackenzie MA; Jordan SA; Budd PS; Jackson IJ
Dev Biol; 1997 Dec; 192(1):99-107. PubMed ID: 9405100
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
